Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Q: Context: After Alaungpaya's death, the new Burmese king Naungdawgyi was embroiled in several rebellions, including that of Gen. Minkhaung Nawrahta, and could not resume the war. The war was inconclusive. For all their work, the Burmese gained little of their original objectives. Siam very much remained a thorn to the stability of Burmese peripheral regions. In the following years, Siam continued to provide support to Mon rebels in the south who raised a major rebellion in 1762 as well as those in Lan Na in the north . The only lasting territorial gain the Burmese achieved was the upper Tenasserim coast, on which they previously had only a nominal claim. Although the Siamese troops no longer openly intruded the border, the Mon rebels continued to operate from the Siamese territory. In 1764, the Mon governor of Tavoy, who was made governor by Alaungpaya only four years earlier, revolted until it was put down in November 1764. Likewise, the instabilities in Lan Na resumed soon after the Burmese army left in February 1764, forcing the army to return again later in the year. The inconclusive nature of the war would lead to the next war in 1765. 
 Question: hich happened first, the nominal claim of the Burmese on the Tenasserim coast, or a territorial claim?

A: a nominal claim
****
Q: Context: Panelefsiniakos B.C., or Paneleusian B.C., is a Greek professional basketball club that is located in Eleusis, Athens, Greece. 
 Question: What city was Panelefsiniakos B.C. formed in?

A: eleusis
****
Q: Context: Chronic liver injury can result in fibrosis that may progress over years to end-stage liver disease. The most effective anti-fibrotic therapy is treatment of the underlying disease, however when not possible, interventions to reverse or slow fibrosis progression are needed. The aim of this study was to study the safety and tolerability of simtuzumab, a monoclonal antibody directed against lysyl oxidase-like 2 (LOXL2) enzyme, in subjects with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or HCV-HIV co-infection and advanced liver disease. Eighteen subjects with advanced liver fibrosis received simtuzumab 700 mg intravenously every 2 weeks for 22 weeks. Transjugular liver biopsies were performed during screening and at the end of treatment to measure hepatic venous pressure gradient (HVPG) and to stage fibrosis. Treatment was well-tolerated with no discontinuations due to adverse events. No significant changes were seen in HVPG or liver biopsy fibrosis score after treatment. Exploratory transcriptional and protein profiling using paired pre- and post-treatment liver biopsy and serum samples suggested up-regulation of TGF-3 and IL-10 pathways with treatment. In this open-label, pilot clinical trial, simtuzumab treatment was well-tolerated in HCV- and HIV-infected subjects with advanced liver disease. Putative modulation of TGF-3 and IL-10 pathways during simtuzumab treatment merits investigation in future trials. 
 Question: What is the drug target for Simtuzumab?

A:
loxl2
****